http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-3124283-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32754540c6c25aa120b79aedffa194bd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c763a416aa2c843fa647df7c6b491188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50fb4b8201f481e00d92a30022dafb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2514e8305c985bff37b11b99e955a91f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef4c24aa656f0b612321193f85f54695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b8aa1f9ec83fc8fb8e12ee0b72c3e26 |
| publicationDate | 2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-3124283-A1 |
| titleOfInvention | Coated ocular implants |
| abstract | The present invention relates to an ocular implant for the controlled release of a therapeutic agent or drug comprising: a) at least 0.1% w/w of a therapeutic agent; b) 5 to 95% w/w of a crosslinked polymer matrix; c) and 0.1 to 40% w/w of a biodegradable polymer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide/caprolactone copolymer, poly-L-lactide-co-caprolactone (PLC) and mixtures, copolymers, and block copolymers thereof;wherein the crosslinked polymer matrix is obtained by crosslinking a photopolymerizable composition selected from the group consisting of fragments or monomers of polyalkylene glycol mono-acrylate, polyalkylene glycol diacrylate, polyalkylene glycol mono-methacrylate and polyalkylene glycol dimethacrylate, and mixtures, copolymers, and block copolymers thereof, characterized in that the ocular implant is at least partially coated on its external surface with at least one coating layer selected from the group consisting of lactide/glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), lactide/caprolactone copolymer, poly (DL-lactide) (PDL), poly (D-lactide), poly-L-lactide-co-caprolactone (PLC) and mixtures, copolymers, and block copolymers thereof; crosslinked fragments or monomers of polyalkylene glycol mono-acrylate, polyalkylene glycol diacrylate, polyalkylene glycol methacrylate and polyalkylene glycol dimethacrylate, and mixtures, copolymers, and block copolymers thereof. |
| priorityDate | 2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 210.